Operating cash outflow of $41.6M in 2026Q3 tracked 103% of the $40.2M net loss, and free cash flow burn more than doubled from roughly -$17M per quarter in 2024, suggesting liquidity is tightening quickly against the $74.8M cash position.
Rapport Therapeutics, Inc. Common Stock (RAPP) cash flow statement — 4-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 |
|---|
| Cash from Operations | -120.85M | -87.47M | -64.83M | -27.18M | -3.24M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | -239.27% | -34.93% | -138.5% | -738.4% | - |
| Net Income | -150.47M | -111.48M | -78.31M | -34.79M | -10.65M |
| Depreciation & Amortization | 902K | 1.02M | 839K | 112K | 15K |
| Stock-Based Compensation | 27.49M | 18.86M | 10.23M | 3.52M | 609.82K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -616K | 636K | 4.82M | 1.32M | 5.3M |
| Working Capital Changes | 1.84M | 3.5M | -2.42M | 2.65M | 1.49M |
| Change in Receivables | -171K | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.28M | 2.21M | -346K | 856K | 0 |
| Cash from Investing | -59.72M | -187.47M | -170.14M | -78.86M | -5.28M |
| Capital Expenditures | -333K | -616K | -2.4M | -1.64M | -284K |
| CapEx % of Revenue | 1.67% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 401K | 0 | 3.21M | 0 | -5M |
| Cash from Financing | 3.96M | 270.79M | 221.63M | 145.14M | 39.69M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 7.9M |
| Equity Issued (Net) | 4.42M | 270.79M | 221.62M | 145.27M | 31.79M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -5K | -1K | 0 | -4K | 0 |
| Other Financing | -453K | 0 | 7K | -134K | 0 |
| Net Change in Cash | -176.6M | -4.16M | -13.34M | 39.09M | 31.16M |
| Free Cash Flow | -121.18M | -88.09M | -67.23M | -28.82M | -3.53M |
| FCF Margin % | -605.91% | - | - | - | - |
| FCF Growth % | -55.58% | -31.02% | -133.31% | -717.27% | - |
| FCF per Share | -2.54 | -2.26 | -3.24 | -19.14 | -0.18 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.78x | 0.83x | 0.78x | 0.30x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying RAPP stock.
Rapport Therapeutics, Inc. Common Stock (RAPP) generated $-87.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Rapport Therapeutics, Inc. Common Stock (RAPP) reported negative free cash flow of $88.1M in 2025, indicating capital requirements exceeded cash from operations.
Rapport Therapeutics, Inc. Common Stock (RAPP) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Rapport Therapeutics, Inc. Common Stock (RAPP) spent $0.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Equity dilution funding dependence
Metrics are mathematically derived from official filings.
Operating Cash Burn Tracks Net Losses Closely
According to reported quarterly figures, RAPP's operating cash flow has consistently run at 65% to 103% of its net loss across the ten quarters, with 2026Q3 showing operating outflows of $41.6M against a $40.2M net loss.
The conversion ratio sits near 1.0 in several recent quarters, which suggests reported losses are almost entirely cash-consuming rather than masked by large non-cash charges. Stock-based compensation of $7.6M in 2026Q3 explains only a modest portion of the gap, so the bulk of the loss reflects real clinical spending. This pattern indicates earnings quality is not the primary concern; the question is the pace of cash consumption relative to available funding.
Free Cash Flow Deficit Widening Into Pivotal Stage
Based on reported figures, RAPP's free cash flow turned from roughly -$17M per quarter in 2024 to -$41.6M in 2026Q3, more than doubling the burn rate as pivotal-stage activity ramped.
Because the company has no revenue base, free cash flow margin is not meaningful and the trajectory is best read in absolute dollars. The sequential acceleration in outflows through 2026 is consistent with RAP-219 pivotal trial costs entering full execution. Investors should monitor whether the burn rate stabilizes or continues to rise, as this directly determines the timing of any further capital raise.
Negligible Capital Intensity Confirms Outsourced Model
As reported in the cash flow statements, RAPP's capital expenditures remained below $0.3M in most quarters, representing near-zero capital intensity against quarterly operating outflows exceeding $40M.
Minimal capex, with D&A of roughly $0.2M per quarter, indicates the company relies on contract research organizations rather than owned laboratory or manufacturing infrastructure. This asset-light structure means cash consumption is driven by variable clinical spend rather than fixed plant commitments. The low capital base offers flexibility to scale trials up or down, though it also leaves the company dependent on external partners for execution timing.
Working Capital Swings Add Quarterly Volatility
Per the reported cash flow data, working capital changes ranged from a $9.5M inflow to a $9.5M outflow across recent quarters, adding noticeable noise to operating cash flow beyond the underlying loss trend.
The lumpy movements, including a $9.5M outflow in 2026Q3 and an $8.5M inflow in 2026Q2, likely reflect the timing of accrued clinical invoices and payables to trial sites. Such swings can make a single quarter's operating cash flow a poor proxy for run rate. Analysts should model burn on a trailing basis to avoid over- or under-stating the underlying consumption pace.
Reported Cash Balance May Overstate Runway
Based on reported figures, the $52.6M cash position appears small relative to the most recent quarterly operating outflow of $41.6M, implying limited coverage of roughly one to two quarters at current burn.
Taken at face value, the cash balance covers only about one quarter of the latest operating burn, which suggests the company is likely to require additional financing in the near term. The reported figure may not capture all liquidity following the 2024 IPO, so the runway conclusion warrants verification against the latest balance sheet. Investors should monitor financing announcements, as dilution appears to be a plausible path to fund pivotal trials.